tsfm-1 Antibody

What applications are TSFM antibodies validated for?

TSFM antibodies are validated for multiple research applications, with specific validation depending on the antibody clone. Based on available research data, TSFM antibodies have demonstrated successful application in:

When designing experiments, it's recommended to perform antibody titration in your specific testing system to obtain optimal results, as the actual working dilution may be sample-dependent .

How should TSFM antibodies be stored to maintain reactivity?

For optimal maintenance of TSFM antibody reactivity, follow these evidence-based storage recommendations:

• Store antibodies at -20°C for long-term storage .

• The antibody solution (typically in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3) remains stable for one year after shipment when properly stored .

• Aliquoting is generally unnecessary for -20°C storage, particularly for the 11701-1-AP antibody .

• Note that some TSFM antibody preparations (20μL sizes) may contain 0.1% BSA as a stabilizer .

Proper storage is critical for maintaining antibody performance in experimental applications. Avoid repeated freeze-thaw cycles, which can lead to protein denaturation and reduced antibody efficacy.

What cell lines and tissues have shown positive results with TSFM antibodies?

TSFM antibodies have demonstrated positive detection across multiple human cell lines and tissues:

Positive Western Blot (WB) detection:

• HeLa cells

• PC-3 cells

• HEK-293 cells

Positive Immunohistochemistry (IHC) detection:

• Human colon cancer tissue

• Human kidney tissue

• Human stomach cancer tissue

Positive Immunofluorescence (IF)/ICC detection:

• HeLa cells

For IHC applications, antigen retrieval is recommended with TE buffer pH 9.0, though alternative antigen retrieval may be performed with citrate buffer pH 6.0 . This information is particularly useful when designing experimental controls and validating antibody performance in new experimental systems.

How should researchers optimize antigen retrieval protocols for TSFM antibody in IHC applications?

Optimizing antigen retrieval for TSFM antibody IHC applications requires a methodical approach:

• Primary Recommended Protocol: Use TE buffer at pH 9.0 for heat-induced epitope retrieval (HIER) . This has been validated as the most effective condition for the 11701-1-AP antibody.

• Alternative Protocol: If TE buffer is unavailable or yields suboptimal results, citrate buffer at pH 6.0 can be used as an alternative .

• Optimization Steps:

  • Begin with the recommended buffer system

  • Test both microwave and pressure cooker-based retrieval methods

  • Adjust retrieval time (typically 10-20 minutes) to balance epitope exposure with tissue preservation

  • For challenging tissues, consider adding 0.05-0.1% Tween-20 to the retrieval buffer to enhance penetration

  • Always include positive control tissues (human colon cancer, kidney, or stomach cancer tissue) that have been validated with TSFM antibodies

• Validation: Compare staining intensity and specificity between different retrieval conditions using serial sections of the same tissue block.

Proper antigen retrieval is critical for accurate TSFM detection, particularly in fixed tissues where protein crosslinking may mask epitopes.

What are the cross-reactivity considerations when using TSFM antibodies across different species?

Understanding cross-reactivity is essential for experimental design when working with samples from different species:

When working with non-human samples, researchers should:

• Select antibodies with validated or highly predicted cross-reactivity for the species of interest

• Validate antibody performance in the specific species before conducting full-scale experiments

• Consider the targeted epitope region when evaluating potential cross-reactivity (e.g., ABIN2780710 targets the C-terminal region , while ABIN2777309 targets the middle region )

• For untested species, perform sequence alignment of the immunogen with the target species' TSFM protein to predict potential cross-reactivity

Cross-reactivity validation is particularly important for comparative studies across species or when working with animal models of mitochondrial disease.

How can researchers validate TSFM antibody specificity for their experimental system?

A rigorous validation approach for TSFM antibody specificity includes:

• Positive Controls:

  • Use cell lines with confirmed TSFM expression (HeLa, PC-3, HEK-293)

  • Include human tissues known to express TSFM (colon, kidney, stomach)

• Negative Controls:

  • Primary antibody omission controls

  • Isotype controls (Rabbit IgG for polyclonal antibodies like 11701-1-AP)

  • Pre-adsorption with the immunizing peptide, if available

• Knockdown/Knockout Validation:

  • Published research has used TSFM knockdown/knockout systems to validate antibody specificity

  • Generate TSFM-knockdown cells using siRNA or CRISPR-Cas9

  • Compare detection signals between wildtype and knockdown samples

• Multiple Antibody Approach:

  • Compare results using antibodies targeting different epitopes (e.g., C-terminal vs. middle region)

  • Consistent detection patterns across different antibodies support specificity

• Western Blot Migration Pattern:

  • Confirm detection of a single band at the expected molecular weight of 35 kDa

  • Additional bands may indicate non-specific binding or post-translational modifications

Proper validation ensures experimental results accurately reflect TSFM biology rather than artifacts of non-specific antibody interactions.

How do TSFM antibodies perform in detecting disease-associated mutations and their effects on protein structure?

The detection of TSFM mutations using antibodies requires special considerations:

• Epitope-Specific Detection Limits:

  • Antibodies targeting regions distant from mutation sites may not distinguish between wildtype and mutant proteins

  • Antibodies recognizing the C-terminal region (e.g., ABIN2780710) or middle region (e.g., ABIN2777309) have different capabilities for detecting structural changes

• Mutation-Specific Approaches:

  • Research has identified novel compound heterozygous variants in TSFM causing severe cardiomyopathy

  • These mutations can destabilize the EF-Ts (TSFM) complex with EF-Tu, leading to reduced steady-state levels of both proteins

  • Quantitative immunoblotting using TSFM antibodies can detect reduced protein levels in patient tissues compared to controls

• Tissue-Specific Expression Patterns:

  • TSFM mutations may manifest differently across tissues

  • Heart tissue shows dramatic steady-state level reduction of both TSFM and EF-Tu proteins in patients with TSFM mutations

  • In contrast, patient fibroblasts show decreased TSFM but upregulated EF-Tu levels and normal oxygen consumption rate, suggesting tissue-specific compensatory mechanisms

• Methodological Approach:

  • Use quantitative Western blotting with appropriate loading controls

  • Compare TSFM levels between affected and unaffected tissues

  • Correlate with functional assays of mitochondrial translation and respiratory chain activity

The ability to detect disease-associated changes in TSFM levels and interactions provides crucial insights into pathophysiological mechanisms of mitochondrial translation defects.

What are the optimal methods for co-immunoprecipitation of TSFM with interacting partners?

For successful co-immunoprecipitation (Co-IP) of TSFM with its interacting partners, particularly EF-Tu:

• Buffer Selection and Optimization:

  • Use mild lysis buffers (e.g., 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol)

  • Include protease inhibitors to prevent degradation

  • Add phosphatase inhibitors if studying phosphorylation-dependent interactions

• Antibody Selection:

  • Choose antibodies validated for immunoprecipitation

  • Consider using antibodies targeting different epitopes (middle region vs. C-terminal) to avoid disrupting specific protein interactions

  • For the TSFM-EFTu interaction, antibodies targeting regions away from the known interaction interface will minimize disruption

• Control Strategies:

  • Include isotype controls (Rabbit IgG for antibodies like 11701-1-AP)

  • Compare wildtype samples with TSFM-depleted samples

  • Pre-clear lysates to reduce non-specific binding

• Detection Strategy:

  • Immunoblot for both TSFM (35 kDa) and expected interaction partners

  • For EF-Tu detection, probe for a protein of approximately 45 kDa

  • Consider reciprocal Co-IP (immunoprecipitate with anti-EF-Tu and detect TSFM)

• Optimization for Weak Interactions:

  • Use chemical crosslinking (e.g., DSP, formaldehyde) to stabilize transient interactions

  • Try various salt concentrations to identify optimal binding conditions

  • Consider native versus denaturing elution conditions based on interaction strength

This methodological approach allows researchers to study the critical interaction between TSFM and EF-Tu, which is essential for understanding mitochondrial translation mechanisms and disease pathology.

How can researchers integrate TSFM antibody staining with other mitochondrial markers for advanced imaging studies?

For sophisticated co-localization and functional imaging studies:

• Multiplex Immunofluorescence Protocol:

  • Primary Antibody Selection: Use TSFM antibodies at validated dilutions (1:50-1:500 for 11701-1-AP)

  • Compatible Mitochondrial Markers:

    • TOMM20 or VDAC1 for mitochondrial outer membrane

    • COX4 or COXIV for inner membrane/respiratory complex

    • mtHSP70 for mitochondrial matrix

    • Alternative markers based on experimental questions

• Sequential Staining Approach:

  • For antibodies from the same host species, use tyramide signal amplification or sequential staining with intermediate blocking steps

  • Order of antibody application:

    1. Apply lower-expressing target antibody first

    2. Apply TSFM antibody (1:50-1:500 dilution)

    3. Apply abundant mitochondrial markers last

• Super-Resolution Microscopy Optimization:

  • For techniques like STED, SIM, or STORM:

    • Use fluorophores with appropriate spectral separation

    • Optimize fixation (4% PFA for 10-15 minutes)

    • Consider stronger permeabilization (0.2% Triton X-100)

    • Use smaller nanobodies or Fab fragments for better penetration and resolution

• Live-Cell Imaging Considerations:

  • For correlative studies combining fixed and live imaging:

    • Start with MitoTracker labeling prior to fixation

    • Follow with TSFM immunofluorescence

    • Use computational alignment to correlate live mitochondrial dynamics with TSFM localization

• Validation Controls:

  • Use TSFM knockdown cells to confirm antibody specificity

  • Include single-stained controls for spectral unmixing

  • Validate in HeLa cells where TSFM antibodies have been confirmed to work for IF/ICC

This advanced imaging approach provides insights into the spatial organization of mitochondrial translation machinery and its relationship to mitochondrial structure and function.

What are the common causes of non-specific binding with TSFM antibodies and how can they be mitigated?

Researchers frequently encounter non-specific binding issues with antibodies. For TSFM antibodies, consider these evidence-based troubleshooting approaches:

• High Background in Western Blotting:

  • Increase blocking stringency (5% BSA or milk in TBST)

  • Optimize antibody dilution (test range of 1:1000-1:4000 for WB with 11701-1-AP)

  • Include 0.1-0.3% Tween-20 in wash buffers

  • Extend washing steps (5 x 5 minutes)

  • Use freshly prepared buffers

• Multiple Bands in Western Blot:

  • Verify sample preparation (complete lysis, fresh protease inhibitors)

  • Confirm expected molecular weight (35 kDa for TSFM)

  • Test antibody in positive control cells (HeLa, PC-3, HEK-293)

  • Consider post-translational modifications or splice variants

  • Validate with a second antibody targeting a different epitope

• Non-specific Staining in IHC/IF:

  • Optimize blocking (10% normal serum from secondary antibody host species)

  • Reduce primary antibody concentration (start with 1:500 dilution)

  • Include 0.3% Triton X-100 in blocking buffer

  • Pre-adsorb antibody with acetone powder from non-relevant tissues

  • Include appropriate negative controls (isotype control, no primary)

• Protocol-Specific Considerations:

  • For WB: Optimize transfer conditions for 35 kDa proteins

  • For IHC: Test both TE buffer pH 9.0 and citrate buffer pH 6.0 for antigen retrieval

  • For IF/ICC: Optimize fixation method (4% PFA vs. methanol)

Systematic optimization of these parameters will help achieve specific detection of TSFM with minimal background interference.

How can researchers accurately quantify TSFM protein levels in different experimental conditions?

For accurate quantification of TSFM protein levels:

• Western Blot Quantification Protocol:

  • Use a dilution series of recombinant TSFM or whole cell lysate to create a standard curve

  • Maintain linear detection range (avoid saturated signals)

  • Normalize to appropriate loading controls:

    • Total protein staining (REVERT, Ponceau S)

    • Housekeeping proteins matched to TSFM subcellular location (mitochondrial)

  • Recommended dilution range: 1:1000-1:4000 for 11701-1-AP

• ELISA-Based Quantification:

  • TSFM antibodies have been validated for ELISA applications

  • Develop sandwich ELISA using:

    • Capture antibody targeting one epitope (e.g., C-terminal)

    • Detection antibody targeting different epitope (e.g., middle region)

  • Include recombinant TSFM protein standards

  • Validate assay specificity using TSFM-depleted samples

• Flow Cytometry/Image Cytometry Approach:

  • Optimize fixation and permeabilization for mitochondrial proteins

  • Use appropriate isotype controls

  • Validate with positive control cell lines (HeLa)

  • Quantify mean fluorescence intensity relative to control samples

• Considerations for Disease Models:

  • In TSFM mutation studies, protein levels may vary dramatically between tissues

  • Heart tissue in patients with TSFM mutations shows severe reduction in steady-state levels

  • Fibroblasts may show compensatory mechanisms with altered EF-Tu levels

  • Include appropriate tissue-matched controls

• Statistical Analysis:

  • Perform at least three independent biological replicates

  • Apply appropriate statistical tests based on data distribution

  • Consider power analysis to determine sample size requirements

These methodological approaches enable reliable quantification of TSFM protein levels, essential for studying its role in mitochondrial translation and disease states.

What strategies can overcome detection challenges in tissues with low TSFM expression?

For enhanced detection of TSFM in tissues with low expression levels:

• Signal Amplification Methods:

  • Tyramide Signal Amplification (TSA):

    • Increases sensitivity up to 100-fold

    • Compatible with standard immunodetection workflows

    • Requires careful optimization of primary antibody dilution (start with 1:500)

  • Polymer-based detection systems:

    • Use HRP or AP-conjugated polymers with multiple secondary antibodies

    • Provides significant amplification without background increase

• Sample Preparation Optimization:

  • For tissue sections:

    • Optimize section thickness (5-7 μm for IHC)

    • Test multiple antigen retrieval methods (both TE buffer pH 9.0 and citrate buffer pH 6.0)

    • Consider extended antigen retrieval times (20-30 minutes)

  • For cell preparations:

    • Concentrate samples through mitochondrial isolation

    • Use gentle permeabilization to preserve mitochondrial structure

• Detection System Selection:

  • Chromogenic substrates:

    • DAB offers good sensitivity and stability

    • AEC provides less sensitivity but cleaner background

  • Fluorescent detection:

    • Use high quantum yield fluorophores (Alexa Fluor 488, 568, 647)

    • Consider signal-enhancing mounting media

    • Employ spectral unmixing to separate autofluorescence

• Technical Enhancements:

  • Proximity Ligation Assay (PLA):

    • Detect TSFM and interacting partners (e.g., EF-Tu)

    • Provides single-molecule sensitivity

    • Useful for visualizing low-abundance complexes

  • RNAscope plus immunodetection:

    • Correlate TSFM mRNA and protein expression

    • Helps distinguish low expression from technical detection failures

• Imaging Optimization:

  • For fluorescence microscopy:

    • Use deconvolution algorithms

    • Employ long exposure times with frame averaging

    • Consider confocal microscopy with photomultiplier gain adjustment

These advanced strategies can significantly improve detection sensitivity for TSFM in low-expression tissues, enabling more comprehensive studies of its tissue-specific roles in health and disease.

How do functional mutations in TSFM affect antibody epitope recognition?

Understanding the impact of TSFM mutations on antibody binding is crucial for accurate detection in disease studies:

• Mutation Impact Analysis:

  • Novel compound heterozygous variants in TSFM have been linked to severe cardiomyopathy

  • These mutations can affect protein stability and interaction with EF-Tu

  • Epitope accessibility may change due to:

    • Conformational alterations

    • Protein degradation

    • Aggregation

    • Subcellular mislocalization

• Epitope-Specific Considerations:

  • Antibodies targeting different regions have varying sensitivity to mutations:

    • C-terminal targeting antibodies (ABIN2780710) : May be affected by C-terminal mutations

    • Middle region targeting antibodies (ABIN2777309) : May detect proteins with C-terminal mutations but miss middle region mutations

  • The immunogen sequence should be compared with known mutation sites:

    • ABIN2780710 immunogen: "VVGMAPLSVG SLDDEPGGEA ETKMLSQPYL LDPSITLGQY VQPQGVSVVD"

    • ABIN2777309 immunogen: "GTMMHCQTLK DQPSAYSKGF LNSSELSGLP AGPDREGSLK DQLALAIGKL"

• Methodological Approach for Mutation Studies:

  • For mutation detection:

    • Use multiple antibodies targeting different epitopes

    • Compare staining patterns between wildtype and mutant samples

    • Correlate with functional assays of mitochondrial translation

  • For quantification in mutation carriers:

    • Western blot with standardized loading controls

    • Include both heterozygous and homozygous samples when available

    • Quantify relative expression levels

• Case Study Evidence:

  • In patients with TSFM mutations, dramatic reduction in steady-state levels of both TSFM and EF-Tu proteins was observed in heart tissue

  • This suggests that antibodies may detect reduced signal intensity rather than altered migration patterns

This understanding helps researchers select appropriate antibodies for studying disease-associated TSFM mutations and interpret results accurately.

What are the best practices for multiplexing TSFM antibodies with other mitochondrial markers in single-cell analysis?

For optimal multiplexing of TSFM with other mitochondrial markers in single-cell studies:

• Panel Design Considerations:

  • Antibody Selection:

    • Choose TSFM antibodies validated for immunofluorescence (e.g., 11701-1-AP)

    • Select complementary mitochondrial markers (structural, functional, dynamic)

    • Consider fluorophore brightness and spectral overlap

  • Panel Examples:

    • TSFM (35kDa) + TOMM20 (outer membrane) + mtHSP70 (matrix) + DAPI (nucleus)

    • TSFM + OXPHOS complex antibodies (CI-CV) + MitoTracker + DAPI

• Technical Optimization for Single-Cell Resolution:

  • Sample Preparation:

    • Optimal fixation: 4% PFA for 10-15 minutes

    • Permeabilization: 0.1-0.3% Triton X-100 for mitochondrial access

    • Blocking: 3-5% BSA with 0.1% Tween-20

  • Staining Protocol:

    • Sequential staining for same-species antibodies

    • TSFM antibody dilution: 1:50-1:500

    • Extended incubation at 4°C (overnight) for better penetration

    • Thorough washing (5 x 5 minutes) between antibodies

• Advanced Imaging Approaches:

  • Confocal Microscopy:

    • Use Airyscan or similar resolution-enhancing technology

    • Z-stack acquisition (0.2-0.3 μm steps)

    • Deconvolution for improved signal-to-noise ratio

  • Super-Resolution Options:

    • STED for co-localization studies (<50 nm resolution)

    • SIM for dynamic studies (100 nm resolution)

    • PALM/STORM for single-molecule resolution

• Quantitative Analysis Strategies:

  • Single-Cell Segmentation:

    • Automated identification of cell boundaries

    • Mitochondrial network segmentation

    • Quantification of TSFM signal intensity per mitochondrial area

  • Co-localization Analysis:

    • Pearson's correlation coefficient

    • Manders' overlap coefficient

    • Object-based co-localization

These approaches enable sophisticated analysis of TSFM distribution and co-localization with other mitochondrial components at the single-cell level, revealing heterogeneity in mitochondrial translation machinery.

How do site-directed mutagenesis studies inform the functional mapping of TSFM antibody epitopes?

Site-directed mutagenesis provides valuable insights into antibody-epitope interactions for TSFM research:

• Mutagenesis Strategy for Epitope Mapping:

  • Similar to approaches used in antibody studies , systematic mutation of amino acid residues in TSFM can:

    • Identify critical binding residues for antibody recognition

    • Map conformational versus linear epitopes

    • Determine epitope accessibility in native versus denatured conditions

  • Priority residues for mutation:

    • Surface-exposed amino acids

    • Charged or polar residues (often critical for antibody binding)

    • Residues unique to human TSFM versus other species

• Technical Approach:

  • Generate a panel of TSFM mutants with single amino acid substitutions

  • Express mutant proteins in cellular systems

  • Test antibody binding using:

    • Western blot (denatured epitopes)

    • Immunoprecipitation (native epitopes)

    • ELISA (quantitative binding assessment)

  • Quantify changes in binding affinity (EC50 shifts)

• Application to Different TSFM Antibodies:

  • For C-terminal targeting antibodies (ABIN2780710) :

    • Focus mutations on the sequence "VVGMAPLSVG SLDDEPGGEA ETKMLSQPYL LDPSITLGQY VQPQGVSVVD"

    • Prioritize charged residues (D, E, K)

  • For middle region targeting antibodies (ABIN2777309) :

    • Focus mutations on the sequence "GTMMHCQTLK DQPSAYSKGF LNSSELSGLP AGPDREGSLK DQLALAIGKL"

    • Prioritize unique or exposed residues

• Insights from Related Antibody Studies:

  • Similar approaches have identified critical binding residues in antibody-antigen interactions

  • In one study, mutants displayed higher dissociation rates (60-1,300 times) and most had faster association rates (1.3-56 times)

  • Such studies can identify amino acid residues that contribute substantially to interaction energy (≥2.5 kcal/mol)

This methodological approach provides detailed understanding of TSFM antibody specificity, guiding epitope selection for new antibody development and informing interpretation of results in mutation studies.

How can TSFM antibodies contribute to understanding tissue-specific manifestations of mitochondrial translation defects?

TSFM antibodies offer powerful tools for investigating tissue-specific aspects of mitochondrial disease:

• Tissue-Specific Expression Patterns:

  • TSFM mutations demonstrate tissue-specific phenotypes, primarily affecting the heart

  • TSFM antibodies can be used to:

    • Map normal TSFM expression across human tissues

    • Quantify tissue-specific changes in TSFM levels in disease states

    • Identify tissue-specific interacting partners through co-immunoprecipitation

• Compensatory Mechanisms Analysis:

  • Research has identified distinct responses to TSFM mutations:

    • Heart tissue: dramatic reduction in both TSFM and EF-Tu levels

    • Fibroblasts: decreased TSFM but up-regulated EF-Tu and induced mitochondrial biogenesis genes

  • TSFM antibodies enable quantitative assessment of:

    • EF-Tu/TSFM ratios across tissues

    • Expression patterns in response to stressors

    • Correlation with respiratory chain subunit expression

• Methodological Approach:

  • Tissue Microarray Analysis:

    • Screen multiple tissues simultaneously

    • Compare normal versus disease samples

    • Quantify TSFM expression relative to mitochondrial content

  • Single-Cell Analysis:

    • Assess cellular heterogeneity within tissues

    • Identify resistant versus vulnerable cell populations

    • Correlate TSFM levels with mitochondrial morphology

• Clinical Translation Potential:

  • TSFM antibodies could support development of:

    • Tissue-specific biomarkers for mitochondrial translation defects

    • Monitoring tools for therapeutic interventions

    • Predictive markers for tissue vulnerability

This research direction would significantly advance understanding of why certain tissues (particularly cardiac tissue) are more vulnerable to TSFM dysfunction, potentially informing targeted therapeutic approaches for mitochondrial translation disorders.

What role can TSFM antibodies play in developing therapeutic approaches for mitochondrial translation disorders?

TSFM antibodies have significant potential for therapeutic development:

• Target Validation and Drug Screening:

  • TSFM antibodies enable:

    • Confirmation of target engagement by potential therapeutics

    • Quantification of TSFM stabilization by small molecules

    • Assessment of EF-Tu/TSFM complex formation in response to treatment

  • High-throughput screening applications:

    • ELISA-based assays for compound screening

    • Cellular imaging assays for phenotypic screening

    • Pull-down assays to identify compounds affecting protein-protein interactions

• Therapeutic Monitoring Tools:

  • For gene therapy approaches:

    • Verify transgene expression levels

    • Confirm proper subcellular localization

    • Assess restoration of mitochondrial translation

  • For protein replacement therapies:

    • Track biodistribution of therapeutic proteins

    • Quantify cellular uptake efficiency

    • Monitor protein stability over time

• Precision Medicine Applications:

  • Patient stratification:

    • Identify cases with reduced versus absent TSFM protein

    • Distinguish primary TSFM defects from secondary effects

    • Correlate protein levels with disease severity

  • Personalized response monitoring:

    • Track TSFM levels in accessible tissues during treatment

    • Correlate with functional mitochondrial parameters

    • Adjust therapy based on molecular response

• Novel Therapeutic Approaches:

  • Antibody-drug conjugates for targeted delivery to mitochondria

  • Bispecific antibodies to stabilize TSFM-EF-Tu interactions

  • Intrabodies expressed within cells to stabilize mutant TSFM proteins

These applications highlight the potential for TSFM antibodies to contribute to therapeutic development beyond their traditional research applications, potentially addressing the unmet medical need in mitochondrial translation disorders.